Complete response to anti-PD1 therapy and chemotherapy in a patient with ALK-rearranged non-small cell lung cancer

被引：0

作者：

Hu, Haoyue ^{[1
]}

Min, Min ^{[2
]}

Dai, Hongchun ^{[3
]}

Tang, Youpan ^{[4
]}

He, Jun ^{[3
]}

机构：

[1] Univ Elect Sci & Technol, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Dept Med Oncol,Med Sch, Chengdu, Sichuan, Peoples R China

[2] Third Hosp Mianyang, Sichuan Mental Hlth Ctr, Dept Pathol, Mianyang, Sichuan, Peoples R China

[3] Third Hosp Mianyang, Sichuan Mental Hlth Ctr, Dept Oncol, Mianyang 621000, Sichuan, Peoples R China

[4] Zhongjiang Peoples Hosp, Dept Gastroenterol, Deyang, Sichuan, Peoples R China

来源：

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY | 2025年 / 18卷 / 01期

关键词：

Non-small cell lung cancer; ALK rearrangement; immunotherapy; PD-1; PD-L1; chemotherapy;

D O I：

10.62347/XWHW6190

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Targeted therapies are effective in non-small cell lung cancer (NSCLC) patients with driver gene mutations. Chemotherapy combined with immunotherapy is also a common treatment strategy in lung cancer. However, in previous studies, patients with ALK (Anaplastic Lymphoma Kinase) rearranged had a low response to immune checkpoint inhibitor (ICI) and the role of immunotherapy in ALK-positive NSCLC patients is unclear. Here, we report a case of a young man with ALK rearranged who demonstrated a complete response to anti-PD1 combination with chemotherapy, which suggests some ALK-rearranged patients with high expression of PD-L1 may permanently benefit from immunotherapy.

引用

页码：37 / 41

页数：5

共 12 条

[1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[2] Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer [J].

Cameron, L. B. ;

Hitchen, N. ;

Chandran, E. ;

Morris, T. ;

Manser, R. ;

Solomon, B. J. ;

Jordan, V .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (01)

[3] EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis [J].

Gainor, Justin F. ;

Shaw, Alice T. ;

Sequist, Lecia V. ;

Fu, Xiujun ;

Azzoli, Christopher G. ;

Piotrowska, Zofia ;

Huynh, Tiffany G. ;

Zhao, Ling ;

Fulton, Linnea ;

Schultz, Katherine R. ;

Howe, Emily ;

Farago, Anna F. ;

Sullivan, Ryan J. ;

Stone, James R. ;

Digumarthy, Subba ;

Moran, Teresa ;

Hata, Aaron N. ;

Yagi, Yukako ;

Yeap, Beow Y. ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari .

CLINICAL CANCER RESEARCH, 2016, 22 (18) :4585-4593

[4] The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) [J].

Golding, Brandon ;

Luu, Anita ;

Jones, Robert ;

Viloria-Petit, Alicia M. .

MOLECULAR CANCER, 2018, 17

[5] Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study [J].

Goto, Yasushi ;

Yamamoto, Nobuyuki ;

Masters, Elizabeth T. ;

Kikkawa, Hironori ;

Mardekian, Jack ;

Wiltshire, Robin ;

Togo, Kanae ;

Ohe, Yuichiro .

ADVANCES IN THERAPY, 2020, 37 (07) :3311-3323

[6] Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status [J].

Koh, Jaemoon ;

Go, Heounjeong ;

Keam, Bhumsuk ;

Kim, Moon-Young ;

Nam, Soo Jeong ;

Kim, Tae Min ;

Lee, Se-Hoon ;

Min, Hye Sook ;

Kim, Young Tae ;

Kim, Dong-Wan ;

Jeon, Yoon Kyung ;

Chung, Doo Hyun .

MODERN PATHOLOGY, 2015, 28 (09) :1154-1166

[7] Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer [J].

Ota, Keiichi ;

Azuma, Koichi ;

Kawahara, Akihiko ;

Hattori, Satoshi ;

Iwama, Eiji ;

Tanizaki, Junko ;

Harada, Taishi ;

Matsumoto, Koichiro ;

Takayama, Koichi ;

Takamori, Shinzo ;

Kage, Masayoshi ;

Hoshino, Tomoaki ;

Nakanishi, Yoichi ;

Okamoto, Isamu .

CLINICAL CANCER RESEARCH, 2015, 21 (17) :4014-4021

[8] Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement [J].

Oya, Yuko ;

Kuroda, Hiroaki ;

Nakada, Takeo ;

Takahashi, Yusuke ;

Sakakura, Noriaki ;

Hida, Toyoaki .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (07)

[9] Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial [J].

Reck, Martin ;

Mok, Tony S. K. ;

Nishio, Makoto ;

Jotte, Robert M. ;

Cappuzzo, Federico ;

Orlandi, Francisco ;

Stroyakovskiy, Daniil ;

Nogami, Naoyuki ;

Rodriguez-Abreu, Delvys ;

Moro-Sibilot, Denis ;

Thomas, Christian A. ;

Barlesi, Fabrice ;

Finley, Gene ;

Lee, Anthony ;

Coleman, Shelley ;

Deng, Yu ;

Kowanetz, Marcin ;

Shankar, Geetha ;

Lin, Wei ;

Socinski, Mark A. .

LANCET RESPIRATORY MEDICINE, 2019, 7 (05) :387-401

[10] Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC [J].

Socinski, M. A. ;

Jotte, R. M. ;

Cappuzzo, F. ;

Orlandi, F. ;

Stroyakovskiy, D. ;

Nogami, N. ;

Rodriguez-Abreu, D. ;

Moro-Sibilot, D. ;

Thomas, C. A. ;

Barlesi, F. ;

Finley, G. ;

Kelsch, C. ;

Lee, A. ;

Coleman, S. ;

Deng, Y. ;

Shen, Y. ;

Kowanetz, M. ;

Lopez-Chavez, A. ;

Sandler, A. ;

Reck, M. ;

Ahualli, A. ;

Jarchum, G. ;

Kaen, D. L. ;

Kahl, S. ;

Kotliar, M. ;

Kowalyszyn, R. D. ;

Lerzo, G. ;

Magri, I ;

Martin, C. ;

Pastor, A. ;

Picon, P. ;

Streich, G. ;

Varela, M. ;

Blinman, P. ;

Boyer, M. ;

Crombie, C. ;

Gauden, S. ;

Gill, S. ;

Hughes, B. ;

John, T. ;

Joshi, A. ;

Kosmider, S. ;

Lewis, C. ;

Millward, M. ;

Nordman, I ;

Nott, L. ;

O'Byrne, K. ;

Parnis, F. ;

Potasz, N. ;

Richardson, G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24) :2288-2301

← 1 2 →